This transaction, aimed at bolstering Jubilant Biosys’ expertise in biologics and antibody-drug conjugates (ADC), and was contingent on the approval of the offer by Pierre Fabre.
March 13, 2025
Jubilant Pharmova shares in focus after USFDA issues five observations to its US-based unit
Share it
